Comparative Study of Frequency of Langerhans Cells in Oral Benign Keratosis and Epithelial Dysplasia
Document Type : Original Articles
Authors
1
Dentist, School of Dentistry, Isfahan University of Medical Sciences, Isfahan, Iran
2
Associate Professor, Dental Research Center, Department of Oral and Maxillofacial Pathology, School of Dentistry, Isfahan University of Medical Sciences, Isfahan, Iran
3
Associate Professor, Dental Materials Research Center, Department of Oral and Maxillofacial Pathology, School of Dentistry, Isfahan University of Medical Sciences, Isfahan, Iran
Abstract
Introduction: Leukoplakia is the most common oral premalignant lesion. Langerhans cells are the first gene-expressing cells that become carcinogenic with early events. The aim of this study was to determine the types of Langerhans cells in benign keratosis and epithelial dysplasia of the oral mucosa by the Cd1a marker and compare them.
Materials and Methods: In a descriptive-analytical, cross-sectional study, the present study examined 40 samples of leukoplakia, including 20 samples with histopathological diagnosis of benign keratosis (group 1) and 20 samples with epithelial dysplasia (group 2) recorded in the archives of the Oral Pathology Department of Isfahan Dental School. To determine the number of Langerhans cells, the samples were immunohistochemically stained with the CD1a marker and the number of Langerhans cells in the lesion was determined by two oral pathologists. The data obtained were statistically analyzed using independent t-tests, chi-square, Mann-Whitney, and Fisher's exact tests. P < 0.05 was considered significant.
Results: The number of Langerhans cells was significantly higher in patients diagnosed with dysplasia of the oral mucosa epithelium (38.70±14.07) than in patients diagnosed with benign keratosis (6.75±2.51) (p < 0.001), but there was no relation with age, gender, and location.
Conclusion: A significant increase in the number of langerhans cells is associated with an increased likelihood of the presence of epithelial dysplasia in leukoplakia. The results of examining these cells can help determine the prognosis and more appropriate treatment methods in patients with leukoplakia.
Materials and Methods: In a descriptive-analytical, cross-sectional study, the present study examined 40 samples of leukoplakia, including 20 samples with histopathological diagnosis of benign keratosis (group 1) and 20 samples with epithelial dysplasia (group 2) recorded in the archives of the Oral Pathology Department of Isfahan Dental School. To determine the number of Langerhans cells, the samples were immunohistochemically stained with the CD1a marker and the number of Langerhans cells in the lesion was determined by two oral pathologists. The data obtained were statistically analyzed using independent t-tests, chi-square, Mann-Whitney, and Fisher's exact tests. P < 0.05 was considered significant.
Results: The number of Langerhans cells was significantly higher in patients diagnosed with dysplasia of the oral mucosa epithelium (38.70±14.07) than in patients diagnosed with benign keratosis (6.75±2.51) (p < 0.001), but there was no relation with age, gender, and location.
Conclusion: A significant increase in the number of langerhans cells is associated with an increased likelihood of the presence of epithelial dysplasia in leukoplakia. The results of examining these cells can help determine the prognosis and more appropriate treatment methods in patients with leukoplakia.
Highlights
Alireza Azizi: PubMed, Google Scholar
Laleh Maleki: PubMed, Google Scholar
Saeedeh Khalesi: PubMed, Google Scholar
Keywords
1. Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol 2017; 3(4): 524-48.
2. Dundar Y, Mandle Q, Raza SN, Lin H-S, Cramer J, Hotaling JM. Submandibular gland invasion by oral cavity cancers: a systematic review. Otolaryngol Head Neck Surg 2019; 161(2): 227-34.
3. Shield KD, Ferlay J, Jemal A, Sankaranarayanan R, Chaturvedi AK, Bray F, et al. The global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2012. CA Cancer J Clin 2017; 67(1): 51-64.
4. Funk GF, Karnell LH, Robinson RA, Zhen WK, Trask DK, Hoffman HT. Presentation, treatment, and outcome of oral cavity cancer: a National Cancer Data Base report. Head Neck 2002; 24(2): 165-80.
5. Saba Y, Aizenbud I, Matanes D, Koren N, Barel O, Zubeidat K, et al. Early antitumor activity of oral Langerhans cells is compromised by a carcinogen. Proc Natl Acad Sci U S A. 2022; 119(3): e2118424119.
6. Silva LC, Fonseca FP, Almeida OP, Mariz BA, Lopes MA, Radhakrishnan R, et al. CD1a+ and CD207+ cells are reduced in oral submucous fibrosis and oral squamous cell carcinoma. Med Oral Patol Oral Cir Bucal 2020; 25(1): e49-e55.
7. Feller L, Lemmer J. Oral leukoplakia as it relates to HPV infection: a review. Int J Dent 2012; 2012: 540561.
8. Wang YP, Chen IC, Wu YH, Wu YC, Chen HM, Yu-Fong Chang J. Langerhans cell counts in oral epithelial dysplasia and their correlation to clinicopathological parameters. J Formos Med Assoc 2017; 116(6): 457-63.
9. Jaitley S, Saraswathi T. Pathophysiology of langerhans cells. J Oral Maxillofac Pathol 2012; 16(2): 239-44.
10. Chandavarkar V, Mishra MN, Sangeetha R, Premalatha BR. The current understanding on langerhans' cells and its role in oral lesions. Contemp Clin Dent 2020; 11(3): 211-6.
11. Jardim JF, Gondak R, Galvis MM, Pinto CAL, Kowalski LP. A decreased peritumoral CD1a+ cell number predicts a worse prognosis in oral squamous cell carcinoma. Histopathol 2018; 72(6): 905-13.
12. Ortner D, Tripp CH, Komenda K, Dubrac S, Zelger B, Hermann M, et al. Langerhans cells and NK cells cooperate in the inhibition of chemical skin carcinogenesis. Oncoimmunol 2016; 6(2): e1260215.
13. Modi BG, Neustadter J, Binda E, Lewis J, Filler RB, Roberts SJ, et al. Langerhans cells facilitate epithelial DNA damage and squamous cell carcinoma. Science 2012; 335(6064): 104-8.
14. Usman SP, Ramakrishnan D, Divya S. Peritumoural and intratumoural distribution of langerhan cell in oral squamous cell carcinoma and its association with known prognostic Factors J Clin of Diagn Res 2023; 17(5): EC12-EC15.
15. Caponio VCA, Zhurakivska K, Lo Muzio L, Troiano G, Cirillo N. The immune cells in the development of oral squamous cell carcinoma. Cancers (Basel) 2023; 15(15): 3779.
16. Upadhyay J, Rao NN, Upadhyay RB. A comparative analysis of langerhans cell in oral epithelial dysplasia and oral squamous cell carcinoma using antibody CD-1a. J Cancer Res Ther 2012; 8: 591–7.
17. Selove W, Picarsic J, Swerdlow SH. Langerin staining identifies most littoral cell angiomas but not most other splenic angiomatous lesions. Hum Pathol 2019; 83: 43-9.
18. Öhman J, Magnusson B, Telemo E, Jontell M, Hasséus B. Langerhans cells and T cells sense cell dysplasia in oral leukoplakias and oral squamous cell carcinomas--evidence for immunosurveillance. Scand J Immunol 2012; 76(1): 39-48.
19. Maloth AK, Dorankula SP, Pasupula AP, Thokala MR, Muddana K, Ramavath R. A comparative immunohistochemical analysis of langerhans cells in oral mucosa, oral lichen planus and oral squamous cell carcinoma. J Clin Diagn Res 2015; 9(7): ZC76-9.
20. Kindt N, Descamps G, Seminerio I, Bellier J, Lechien JR, Pottier C, et al. Langerhans cell number is a strong and independent prognostic factor for head and neck squamous cell carcinomas. Oral Oncol 2016; 62: 1-10.
21. Lasisi TJ, Oluwasola AO, Lasisi OA, Akang EE. Association between langerhans cells population and histological grade of oral squamous cell carcinoma. J Oral Maxillofac Pathol 2013; 17(3): 329-33.
22. Singh SS, Chettiankandy TJ, Rodricks K, Bisht S. Correlation between Langerhans cells and mast cells in Oral Squamous Cell Carcinoma – An insight. IOSR-JDMS. 2020;19(3):1-7
23. Yildiz P, Sonmez FC, Tosuner Z, Aytugar E. Evaluation of langerhans cell density in oral lichen planus and squamous cell carcinoma. Konuralp Med J 2020;12(3): 481-5.
24. Dafar A, Siarov A, Mostaghimi Y, Robledo-Sierra J, De Lara S, Giglio D, et al. Langerhans Cells, T Cells, and B Cells in Oral Lichen Planus and Oral Leukoplakia. Int J Dent. 2022;2022(1):5430309.
25. Sugaya M, Loré K, Koup RA, Douek DC, Blauvelt A. HIV‑infected Langerhans cells preferentially transmit virus to proliferating autologous CD4+ memory T cells located within Langerhans cell‑T cell clusters. J Immunol 2004;172:2219‑24.
26. Upadhyay J, Upadhyay RB, Agrawal P, Jaitley S, Shekhar R. Langerhans cells and their role in oral mucosal diseases. North American J Med Sci 2013 ;5(9):505.
27. Van der Waal I. Oral leukoplakia, the ongoing discussion on definition and terminology. Medicina Oral, Patol Oral y Cirugia Bucal 2015 ;20(6):e685.
28. Martin S, Greenberg M, Glick M, Ship J. Burket's Oral Medicine. Diagnosis and Treatment. 11th ed Hamilton: B.C. Inc; Decker 2008: P.191-206.
29. Robledo‐Sierra J, Landin‐Wilhelmsen K, Filipsson Nyström H, Eggertsen R, Larsson L, Dafar A,etal. A mechanistic linkage between oral lichen planus and autoimmune thyroid disease. Oral Dis2018;24(6):1001‐11.
